All Stories

  1. Antigenic Drift of Hemagglutinin and Neuraminidase in seasonal H1N1 influenza Viruses from Saudi Arabia in 2014‐2015
  2. M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection
  3. Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies
  4. Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
  5. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
  6. Cutting Edge Approaches Toward Novel and Cross-Protective Influenza Vaccines
  7. The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections
  8. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus
  9. Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection
  10. M2e-based universal influenza A vaccine
  11. CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine
  12. LIND/ABIN-3 Is a Novel Lipopolysaccharide-inducible Inhibitor of NF- B Activation
  13. 2′,5′-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome
  14. Adenoviral Gene Transfer of the NF- B Inhibitory Protein ABIN-1 Decreases Allergic Airway Inflammation in a Murine Asthma Model
  15. Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality
  16. In vivoanti-tumour activity of recombinant MVM parvoviral vectors carrying the human interleukin-2 cDNA
  17. Ribonuclease L
  18. Cloning and Sequencing of Defective Particles Derived from the Autonomous Parvovirus Minute Virus of Mice for the Construction of Vectors with Minimal cis-Acting Sequences
  19. Helper-free generation of new oncotropic and oncotoxic vectors derived from MVM autonomous parvovirus
  20. Influence of Sequence and Size of DNA on Packaging Efficiency of Parvovirus MVM-Based Vectors